Head-to-head · WeighScore
NP2GO vs Hims & Hers
The verdict
Too close to call — both grade 80/100 (B−).
NP2GO and Hims & Hers land on the same WeighScore, so neither clears the other on our six graded dimensions. Hims & Hers sits one line higher on the board (#22 vs #23) on the underlying tiebreak, but it's a genuine coin-flip — pick on the factors and prices that matter most to you below.
Both are editorial reviews with no commercial relationship.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | NP2GO | Hims & Hers |
|---|---|---|
| WeighScore | 80/100 | 80/100 |
| Grade | B− | B− |
| Scorecard rank | #23 | #22 |
| Semaglutide | $150/mo | $199/mo |
| Tirzepatide | $250/mo | Not disclosed |
| Coverage | 40 states | All 50 states |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Injection only |
| Relationship | Editorial | Editorial |
Graded #23 · B−
Strengths
- Both molecules
- 40-state footprint
- Transparent listed pricing
Where it loses points
- Not LegitScript-verified
- Upper-mid pricing ($150/$250)
- Not all 50 states
Graded #22 · B−
Strengths
- Nationwide
- Polished app
- Strong brand trust
Where it loses points
- Tirzepatide pricing inconsistently disclosed
- Industry-wide compounding scrutiny
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 25 providers, CoreAge Rx grades highest at 94/100 (A). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.